Pemigatinib

Molecular mass: 487.508 g/mol 

Therapeutic indications

Pemigatinib is indicated for:

Cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement

Population group: only adults (18 years old or older)

Pemigatinib monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Pemigatinib is contraindicated in the following cases:

Lactation

Lactation

St John's wort

Hypericum perforatum (St John's Wort)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.